On being the right size: The impact of population size and stochastic effects on the evolution of drug resistance in hospitals and the community

PLoS Pathogens

Volumn 7, Issue 4, 2011, Pages

  Kouyos, Roger D ^a,b   zur Wiesch, Pia Abel ^a   Bonhoeffer, Sebastian ^a  

^a ETH ZURICH   (Switzerland)

^b PRINCETON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTHELMINTIC AGENT; CAENORHABDITIS ELEGANS PROTEIN; DEPSIPEPTIDE; EMODEPSIDE; LARGE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; MYCOTOXIN; SLO 1 PROTEIN, C ELEGANS; SLO-1 PROTEIN, C ELEGANS; TREMORTIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BIOLOGICAL MODEL; CONTROLLED STUDY; DISEASE CARRIER; ENVIRONMENTAL EXPOSURE; HOSPITAL ADMISSION; HOSPITAL BED CAPACITY; HOSPITAL DISCHARGE; HUMAN; INFECTION CONTROL; IRELAND; POPULATION MODEL; POPULATION SIZE; SPECIES EXTINCTION; STOCHASTIC MODEL; UNITED STATES; ANCYLOSTOMA; ANCYLOSTOMIASIS; ANIMAL; CAENORHABDITIS ELEGANS; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; HAEMONCHOSIS; HAEMONCHUS; METABOLISM; METHODOLOGY; MOTOR ACTIVITY; MUTATION; SPECIES DIFFERENCE;

ANCYLOSTOMA; ANCYLOSTOMIASIS; ANIMALS; ANTHELMINTICS; CAENORHABDITIS ELEGANS; CAENORHABDITIS ELEGANS PROTEINS; DEPSIPEPTIDES; DRUG ANTAGONISM; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE; GENE EXPRESSION REGULATION; HAEMONCHIASIS; HAEMONCHUS; LARGE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; MOTOR ACTIVITY; MUTATION; MYCOTOXINS; SPECIES SPECIFICITY;

EID: 79955779574     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1001334     Document Type: Article

References (34)

1. Chambers HF, Deleo FR, (2009) Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol 7: 629-641.
2. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, et al. (2003) Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 289: 885-888.
3. Abel zur Wiesch P, Kouyos R, Engelstädter J, Regoes R, Bonhoeffer S, (2011) Population biological principles of drug-resistance evolution in infectious diseases. Lancet Infect Dis 11: 235-247.
4. Smith DL, Levin SA, Laxminarayan R, (2005) Strategic interactions in multi-institutional epidemics of antibiotic resistance. Proc Natl Acad Sci U S A 102: 3153-3158.
5. Nicolle L, (2001) Infection control programmes to contain antimicrobial resistance. WHO Available:http://www.who.int/csr/resources/publications/drugresist/infection_control.pdf.
6. Deleo FR, Otto M, Kreiswirth BN, Chambers HF, (2010) Community-associated meticillin-resistant Staphylococcus aureus. Lancet 375: 1557-1568.
7. Opatowski L, Mandel J, Varon E, Boelle PY, Temime L, et al. (2010) Antibiotic dose impact on resistance selection in the community: a mathematical model of beta-lactams and Streptococcus pneumoniae dynamics. Antimicrob Agents Chemother 54: 2330-2337.
8. Goossens H, Ferech M, Vander Stichele R, Elseviers M, (2005) Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 365: 579-587.
9. Asensio A, Canton R, Vaque J, Rossello J, Calbo F, et al. (2006) Nosocomial and community-acquired meticillin-resistant Staphylococcus aureus infections in hospitalized patients (Spain, 1993-2003). J Hosp Infect 63: 465-471.
10. Bhavnani SM, Hammel JP, Forrest A, Jones RN, Ambrose PG, (2003) Relationships between patient- and institution-specific variables and decreased antimicrobial susceptibility of Gram-negative pathogens. Clin Infect Dis 37: 344-350.
11. Chastre J, (2008) Evolving problems with resistant pathogens. Clin Microbiol Infect 14 (Suppl 3): 3-14.
12. Poirel L, Nordmann P, (2006) Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect 12: 826-836.
13. Zoutman DE, Ford BD, (2005) The relationship between hospital infection surveillance and control activities and antibiotic-resistant pathogen rates. Am J Infect Control 33: 1-5.
14. de With K, Meyer E, Steib-Bauert M, Schwab F, Daschner FD, et al. (2006) Antibiotic use in two cohorts of German intensive care units. J Hosp Infect 64: 231-237.
15. Bergstrom CT, Lo M, Lipsitch M, (2004) Ecological theory suggests that antimicrobial cycling will not reduce antimicrobial resistance in hospitals. Proc Natl Acad Sci U S A 101: 13285-13290.
16. Bonhoeffer S, Lipsitch M, Levin BR, (1997) Evaluating treatment protocols to prevent antibiotic resistance. Proc Natl Acad Sci U S A 94: 12106-12111.
17. Gillespie DT, (2001) Approximate accelerated stochastic simulation of chemically reacting systems. J Chem Phys 115: 1716-1733.
18. Gillespie DT, (1976) General Method for Numerically Simulating Stochastic Time Evolution of Coupled Chemical-Reactions. J Comput Phys 22: 403-434.
19. Health Service Executive Ireland (2011) Healthcare-Associated Infection and Antimicrobial Resistance-Related Data from Acute Public Hospitals in Ireland, 2006-2007. Available: http://www.hse.ie/eng/services/newscentre/2008_Archive/May_2008/HSE_publishes_Health_Care_Associated_Infection_statistics.html.
20. Pennsylvania Health Care Cost Containment Council (2011) Hospital-acquired Infections in Pennsylvania 2005, 2006 & 2007. Available: http://www.phc4.org/reports/hai/.
21. Fisher RA, (1930) The Genetical Theory of Natural Selection. Oxford Clarendon Press.
22. Neely AN, Maley MP, (2000) Survival of enterococci and staphylococci on hospital fabrics and plastic. J Clin Microbiol 38: 724-726.
23. Leverstein-van Hall MA, Blok HE, Paauw A, Fluit AC, Troelstra A, et al. (2006) Extensive hospital-wide spread of a multidrug-resistant enterobacter cloacae clone, with late detection due to a variable antibiogram and frequent patient transfer. J Clin Microbiol 44: 518-524.
24. Ahgren B, (2008) Is it better to be big? The reconfiguration of 21st century hospitals: Responses to a hospital merger in Sweden. Health Policy 87: 92-99.
25. Keeler EB, Rubenstein LV, Kahn KL, Draper D, Harrison ER, et al. (1992) Hospital Characteristics and Quality of Care. JAMA 268: 1709-1714.
26. McCallion G, Glass JC, Jackson R, Kerr CA, McKillop DG, (2000) Investigating productivity change and hospital size: a nonparametric frontier approach. Appl Econ 32: 161-174.
27. Carr BG, Goyal M, Band RA, Gaieski DF, Abella BS, et al. (2009) A national analysis of the relationship between hospital factors and post-cardiac arrest mortality. Intensive Care Med 35: 505-511.
28. Luciani F, Sisson SA, Jiang H, Francis AR, Tanaka MM, (2009) The epidemiological fitness cost of drug resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 106: 14711-14715.
29. Johnsen PJ, Townsend JP, Bohn T, Simonsen GS, Sundsfjord A, et al. (2011) Retrospective evidence for a biological cost of vancomycin resistance determinants in the absence of glycopeptide selective pressures. J Antimicrob Chemother 66: 608-610.
30. Trindade S, Sousa A, Xavier KB, Dionisio F, Ferreira MG, et al. (2009) Positive epistasis drives the acquisition of multidrug resistance. PLoS Genet 5: e1000578.
31. Hartl DL, Clark AG, (2007) Principles of Population Genetics. Sunderland Sinauer Associates.
32. Lucet JC, Paoletti X, Demontpion C, Degrave M, Vanjak D, et al. (2009) Carriage of methicillin-resistant Staphylococcus aureus in home care settings: prevalence, duration, and transmission to household members. Arch Intern Med 169: 1372-1378.
33. van Loon HJ, Vriens MR, Fluit AC, Troelstra A, van der Werken C, et al. (2005) Antibiotic rotation and development of gram-negative antibiotic resistance. Am J Respir Crit Care Med 171: 480-487.
34. Cars O, Molstad S, Melander A, (2001) Variation in antibiotic use in the European Union. Lancet 357: 1851-1853.